Allogeneic stem cell transplantation as a new treatment option for patients with severe Bernard-Soulier Syndrome

• References

• 1 Bernard J, Soulier J P. Sur une nouvelle varieté de dystrophie thrombocytairehemorrhagipare congenitale. Semin Hop Paris 1948; 24: 3217.
• 2 Lopez JA, Andrews RK, Afshar-Kharghan V. et al. Bernard-Soulier-Syndrome. Blood 1998; 91: 4397-418.
• 3 Caen JP, Levy-Toledano S. Interaction between platelets and von Willebrand factor provides a new scheme for primary haemostasis. Nat New Biol 1973; 244: 159-60.
• 4 Andrews RK, José A, Berndt MC. Molecular mechanisms of platelet adhesion and Activation. Int J Biochem Cell Biol 1997; 29: 91-105.
• 5 Cuthbert RJ, Watson HH, Handa SI. et al. DDAVP shortens the bleeding time in Bernard-Soulier syndrome. Thromb Res 1988; 49: 649-50.
• 6 Kehmali S, Canatan D, Uysal Z. et al. DDAVP shortens bleeding time in Bernard-Soulier syndrome. Thromb Haemost 1994; 71: 675.
• 7 Greinacher A, Pötzsch B, Kiefel V. et al. Evidence that DDAVP transiently improves hemostasis in Bernard-Soulier syndrome independent of von-WillebrandFactor. Ann Hematol 1993; 67: 149-50.
• 8 Linden MD, FrelingerA L, Barnard MR. et al. Application of flow cytometry to platelet disorders. Semin Thromb Hemost 2004; 30: 501-11.
• 9 Carreras E. Early Complications after HSCT. In: The EBMT Handbook. Haematopoietic Stem Cell Transplantation. Apperly J, Carreras E, Gluckman E, Gratwohl A, Masszi T. 2004. Revised Edition. Forum Service Editore; Genua: 2004: 133-45.
• 10 Locatelli F, Rossi G, Balduini C. Hematopoietic stem-cell transplantation for the Bernard-Soulier-Syndrome. Ann Int Med 2003; 138: 79.